HeartFlow
HeartFlow Inc is an American multinational medical technology and digital health enterprise specializing in the research, development, and provision of advanced cardiovascular diagnostic software and non-invasive artificial intelligence (AI) imaging analysis solutions, prominently featuring the HeartFlow Analysis platform which translates standard coronary computed tomography angiography (CTA) scans into three-dimensional color-coded models displaying precise fractional flow reserve (FFR-CT) values to evaluate coronary artery disease without invasive procedures. The company operates advanced medical software engineering and cloud-based analysis facilities. Its core business operations encompass medical software development, AI cardiovascular analytics, cloud processing of clinical imaging, and healthcare regulatory compliance. Revenue is derived primarily from software-as-a-service (SaaS) per-analysis diagnostic fees and hospital licensing agreements. HeartFlow holds a leading global market position in non-invasive cardiovascular AI diagnostics. The company is headquartered in Mountain View, California, United States, operating as a premier medical technology enterprise.
4 of the funds FundTelligence covers report a position in HeartFlow.
- Legal name
- HeartFlow Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
- Exposure themes
- Artificial Intelligence, Diagnostics & Imaging, Healthcare
Funds holding HeartFlow
- BNP Health Care Innovators — BNP Paribas · 0.7 % (full portfolio disclosed, June 2026)
- BNP US Small Cap — BNP Paribas · 0.58 % (full portfolio disclosed, June 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.06 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.03 % (full portfolio disclosed, September 2026)